2025-10-24
Our portfolio company Navinci Diagnostics is featured in a recent BioStock article, where CEO Jenny Sundqvist discusses the company’s innovative approach to understanding how proteins truly interact.
Navinci’s technology, based on its proprietary in situ proximity ligation assay (PLA), allows researchers to visualize both individual proteins and their interactions directly in tissue and cells. This enables a deeper understanding of biological mechanisms and drug effects, marking an important step forward in the fast-growing field of spatial proteomics, which Nature named “Method of the Year 2024.”
The company’s roots trace back to the same scientific foundation as Olink, but Navinci has since advanced the field further with a platform-independent and multiplexing solution — allowing simultaneous analysis of multiple proteins and interactions using existing lab equipment. This unique capability is already driving strong market demand: Navinci reported 37 percent annual growth since 2021 and expects revenues of SEK 17–19 million in 2025.
Looking ahead, Navinci is expanding its multiplexing services and preparing to launch next-generation multiplexing kits in 2026, enabling researchers to perform advanced interaction analyses in-house. The company also plans to further strengthen its data analysis capabilities and continue growing its expert team to support its ambitious long-term strategy.